Studies to date have generally demonstrated limited efficacy of MEK1/2 selective inhibitors in RAS mutant cancers, and trametinib specifically did not demonstrate clinical efficacy in KRAS mutant PDAC [119]. Here, MAP2K1 is linked to cancer.